Effectiveness and Cost-Effectiveness of Erlotinib Versus Gefitinib in First-Line Treatment of Epidermal Growth Factor Receptor–activating Mutation-Positive Non–small-Cell Lung Cancer Patients in Hong Kong

Hong Kong Medical Journal - Hong Kong

doi 10.12809/hkmj133986